The United States government has resolved to cease sponsorship for 22 projects that focus on the development and production of mRNA-based vaccines. These vaccines are instrumental in combating respiratory illnesses such as COVID-19 and influenza. Health Secretary Robert F. Kennedy Jr. announced this initiative, revealing concerns about the vaccines’ efficiency. This decision reflects a broader trend in weaving vaccine skepticism into U.S. health policies.
In his statement, Kennedy declared, “We assessed the evidence, engaged with the experts, and acted accordingly.” Advising the termination of 22 mRNA vaccine development investments by the Health department’s Biomedical Advanced Research and Development Authority (BARDA), he asserted that these investments are no longer viable due to inadequate protection against upper-respiratory infections such as COVID and flu. The overall cost of the halted projects is nearing $500 million, according to the Department of Health and Human Services (HHS).
In a video disseminated across social media platforms, Kennedy denounced mRNA vaccines, particularly scrutinizing endeavors led by prominent pharmaceutical companies, such as Pfizer and Moderna. These companies develop protective vaccines against influenza, COVID-19, and H5N1. Kennedy outlined that to replace these ineffective mRNA programs, there is a growing emphasis on developing safer, more comprehensive vaccine strategies, such as whole-virus vaccines and novel platforms that stand firm against viral mutations.
Kennedy asserted, “Let me be categorically clear: HHS endorses safe, effective vaccines for every American who desires them.” The use of mRNA technology currently extends beyond mere infectious disease vaccines, with global researchers exploring its potential in developing cancer immunotherapies. The HHS affirmed that other applications of mRNA technology will remain unaffected by this proclamation.
Source: https://www.dw.com/en/us-cancels-mrna-vaccine-contracts-worth-500-million/a-73542725?maca=en-rss-en-all-1573-rdf
